Earnings summaries and quarterly performance for MERIT MEDICAL SYSTEMS.
Executive leadership at MERIT MEDICAL SYSTEMS.
Martha G. Aronson
Detailed
President and Chief Executive Officer
CEO
BG
Brian G. Lloyd
Detailed
Chief Legal Officer and Corporate Secretary
FP
Fred P. Lampropoulos
Detailed
Executive Chairman of the Board
MJ
Michel J. Voigt
Detailed
Chief Human Resources Officer
NW
Neil W. Peterson
Detailed
Chief Operating Officer
RP
Raul Parra
Detailed
Chief Financial Officer and Treasurer
Board of directors at MERIT MEDICAL SYSTEMS.
DK
David K. Floyd
Detailed
Director
FA
F. Ann Millner
Detailed
Lead Independent Director
LS
Laura S. Kaiser
Detailed
Director
LJ
Lonny J. Carpenter
Detailed
Director
LN
Lynne N. Ward
Detailed
Director
MR
Michael R. McDonnell
Detailed
Director
SM
Silvia M. Perez
Detailed
Director
SC
Stephen C. Evans
Detailed
Director
TJ
Thomas J. Gunderson
Detailed
Director
Research analysts who have asked questions during MERIT MEDICAL SYSTEMS earnings calls.
DR
David Rescott
Baird
4 questions for MMSI
Also covers: HAE, INSP, IRTC +7 more
James Sidoti
Sidoti & Company
4 questions for MMSI
Also covers: ANIK, ASRT, GAIA +10 more
Jason Bednar
Piper Sandler Companies
4 questions for MMSI
Also covers: ALGN, COO, EDAP +15 more
Jayson Bedford
Raymond James
4 questions for MMSI
Also covers: AXGN, DXCM, IART +7 more
MP
Michael Petusky
Barrington Research
4 questions for MMSI
Also covers: ANIK, HAE, HSIC +8 more
SL
Steven Lichtman
Oppenheimer & Co. Inc.
4 questions for MMSI
Also covers: ALC, ANGO, COO +12 more
JY
John Young
Canaccord Genuity - Global Capital Markets
3 questions for MMSI
Also covers: ANGO, CVRX, IRTC +2 more
Michael Matson
Needham & Company
3 questions for MMSI
Also covers: AORT, ATRC, CNMD +22 more
CB
Craig Bijou
Bank of America Securities
2 questions for MMSI
Also covers: BLCO, COO, FNA +9 more
GK
Gursimran Kaur
Wells Fargo & Company
2 questions for MMSI
Also covers: STAA
RM
Robert Marcus
JPMorgan Chase & Co.
2 questions for MMSI
Also covers: ABT, BAX, BDX +21 more
LB
Lawrence Biegelsen
Wells Fargo
1 question for MMSI
Also covers: ABT, ALC, BAX +16 more
Mike Matson
Needham & Company, LLC
1 question for MMSI
Also covers: CNMD, ENOV, ESTA +16 more
Recent press releases and 8-K filings for MMSI.
Merit Medical Discusses 2025 Financial Performance, Strategic Outlook, and Leadership Transition
MMSI
CEO Change
Board Change
Guidance Update
- Martha Aronson was appointed CEO on October 3, 2025, succeeding the company's founder, and F. Ann Millner transitioned to Chairman of the Board.
- Merit Medical achieved $1.5 billion in revenues for 2025, an 11% increase, and pre-announced preliminary Q4 2025 revenue between $389 million-$395 million with 8%-10% constant currency growth.
- The company is tracking towards its Continued Growth Initiatives (CGI) targets for FY23-2026, aiming for a 5%-7% revenue CAGR, 20%-22% non-GAAP operating margin, and more than $400 million in cumulative free cash flow.
- Merit Medical plans to continue its M&A strategy, focusing on strategic tuck-in acquisitions, potentially slightly larger, but not transformational deals, supported by a strong balance sheet.
- The company's first PMA-approved therapeutic product, WRAPSODY, has an initial U.S. addressable market of approximately 95,000 stent units annually, and despite reimbursement adjustments, it remains margin accretive.
Jan 14, 2026, 12:30 AM
Merit Medical Discusses 2025 Performance, 2026 Outlook, and Strategic Priorities at J.P. Morgan Healthcare Conference
MMSI
CEO Change
Guidance Update
M&A
- Martha Aronson was appointed CEO on October 3, 2025, succeeding founder Fred Lampropoulos, with F. Ann Millner becoming Chairman of the Board, indicating a shift to a founder-inspired organization.
- Merit Medical delivered $1.5 billion in revenue for full-year 2025, up 11%, and preliminary Q4 2025 revenue of $389 million-$395 million with 8%-10% constant currency growth. The company is on track for its FY23-2026 Continued Growth Initiatives, targeting a 5%-7% revenue CAGR, 20%-22% non-GAAP operating margin, and over $400 million in cumulative free cash flow.
- The company plans to continue its M&A strategy, having invested over $1 billion since 2016, focusing on strategic tuck-ins and potentially slightly larger deals, supported by a strong balance sheet with leverage just under two times. M&A remains the primary use of cash.
- Therapeutic products, which comprise one-third of global revenues, are a key growth driver, achieving a 19% compound annual growth rate over the last three years, significantly outpacing foundational products at 6% CAGR.
Jan 14, 2026, 12:30 AM
Merit Medical Systems Appoints New Board Chair and Announces Preliminary Q4 2025 Revenue
MMSI
Board Change
Earnings
Guidance Update
- Merit Medical Systems, Inc. appointed F. Ann Millner, Ed.D. as Chair of the Board, effective January 5, 2026, following the resignation of Fred P. Lampropoulos on January 4, 2026.
- The company reported preliminary unaudited revenue for the fourth quarter of 2025 as follows :
| Metric | Q4 2025 |
|---|---|
| Reported Revenue ($USD Millions) | $389 - $395 |
| Reported Revenue Year-over-Year Growth (%) | 10% - 11% |
| Constant Currency Revenue ($USD Millions) | $384.6 - $390.6 |
| Constant Currency Revenue Year-over-Year Growth (%) | 8% - 10% |
- Merit plans to announce its full financial results for the quarter and year ended December 31, 2025, and issue fiscal year 2026 guidance on Tuesday, February 24, 2026.
Jan 8, 2026, 9:33 PM
Merit Medical Appoints New Board Chair and Announces Preliminary Q4 2025 Revenue
MMSI
Board Change
Earnings
Guidance Update
- F. Ann Millner was appointed Chair of the Board of Merit Medical Systems, Inc. effective January 5, 2026, succeeding Fred P. Lampropoulos who resigned on January 4, 2026.
- The company reported preliminary unaudited revenue for the fourth quarter of 2025 in the range of approximately $389 million to $395 million, representing a year-over-year increase of approximately 10% to 11%.
- Merit Medical Systems plans to announce its full financial results for the quarter and year ended December 31, 2025, and issue fiscal year 2026 guidance on February 24, 2026.
Jan 8, 2026, 9:05 PM
MMI to Present at J.P. Morgan Healthcare Conference, Highlights 2025 Milestones
MMSI
Product Launch
New Projects/Investments
- MMI (Medical Microinstruments, Inc.) will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, marking its fourth consecutive year presenting in the private company track.
- CEO Mark Toland will provide a company update on Monday, January 12 at 9:00 AM PT, focusing on commercial progress, platform innovation, and clinical advancement of the Symani® Surgical System.
- In 2025, MMI achieved significant milestones, including FDA clearance and first U.S. clinical use of robotic microsurgical dissection instruments, and the establishment of the first reimbursement code for surgical lymphatic procedures.
- The company also initiated major U.S. clinical trials, such as PRECISE and two neurosurgery studies, expanding its clinical advancement efforts.
Jan 6, 2026, 2:00 PM
MMI receives FDA clearance and completes first U.S. clinical use
MMSI
Product Launch
New Projects/Investments
- MMI (Medical Microinstruments, Inc.) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its NanoWrist® Scissors and Forceps.
- These instruments are indicated for soft tissue dissection and expand the capabilities of the Symani® Surgical System for complex surgery.
- The first U.S. clinical use of the cleared instruments was completed at Tampa General Hospital, performing the world's first fully robotic-assisted lymphovenous bypass (LVB) from incision to closure.
- The NanoWrist Scissors and Forceps are described as the world's first and smallest fully wristed robotic instruments specifically designed for dissection in open microsurgery.
Dec 9, 2025, 2:30 PM
Merit Medical Systems Discusses Strategic Direction, CGI Goals, and Wrapsody Launch
MMSI
CEO Change
Guidance Update
Product Launch
- CEO Martha Aronson, who joined two months prior, confirmed the company will continue its strategy of organic and inorganic growth, with a focus on strategic planning for beyond 2026.
- CFO Raul Parra expressed confidence in achieving the Continuous Growth Initiatives (CGI) goals through 2026, including 5%-7% revenue CAGR, 20%-22% operating margin, and a minimum of $400 million in free cash flow, despite an anticipated $13 million-$15 million tariff impact for next year.
- The Wrapsody commercial launch is "going well" in its early weeks, with adjusted pricing corridors to expand physician access, and the company plans to guide to Wrapsody revenue for 2026.
- In China, volume growth remains strong, though volume-based purchasing (VBP) has reduced sales as a percentage of total from 13% to 10%, with the impact expected to lessen in 2025 and 2026 compared to 2024.
- The company's M&A strategy will continue to be acquisitive, focusing on key platforms and seeking both strategic and financial fits.
Dec 3, 2025, 8:00 PM
Merit Medical Discusses Strategy, CGI Goals, Wrapsody Launch, and China Outlook
MMSI
Guidance Update
Product Launch
M&A
- Merit Medical's new CEO, Martha Aronson, who joined two months prior, affirmed the company's commitment to its established strategy of organic and inorganic growth and is forming a new executive leadership team to plan beyond 2026.
- CFO Raul Parra expressed confidence in achieving the Continuous Growth Initiatives (CGI) goals through 2026, targeting a 5%-7% revenue CAGR, 20%-22% operating margin, and a minimum of $400 million in free cash flow.
- The Wrapsody commercial launch is "going well" in its early days, following a strategic pivot to adjust pricing corridors. The company will provide Wrapsody revenue guidance for 2026 but not other metrics.
- In the China market, despite volume-based purchasing (VBP) reducing sales as a percentage, volume growth remains strong. The company anticipates the VBP impact will be less severe in 2025 than 2024, and even less in 2026 than 2025, suggesting an improving outlook.
- The M&A strategy will evolve to be more intentional, focusing on key platforms and proactively seeking acquisitions that offer both strategic and financial fit.
Dec 3, 2025, 8:00 PM
Merit Medical Systems Updates WRAPSODY Commercial Strategy
MMSI
Guidance Update
Product Launch
New Projects/Investments
- The U.S. Centers for Medicare & Medicaid Services (CMS) deferred Merit Medical Systems, Inc.'s application for Transitional Pass-Through (TPT) incremental payment for its WRAPSODY® Cell-Impermeable Endoprosthesis to the Calendar Year 2027 Outpatient Prospective Payment System rule, making January 1, 2027, the earliest possible effective date.
- In response to the deferral, Merit Medical has withdrawn its TPT application and will immediately begin full commercialization of the WRAPSODY CIE in the U.S., enacting a new commercial strategy to increase patient access and optimize adoption.
- Merit Medical continues to forecast U.S. revenue from WRAPSODY CIE sales for the full year 2025 period in the range of $2 million to $4 million.
Nov 13, 2025, 10:14 PM
MMI Receives FDA Approval for Alzheimer's Robotic Microsurgical Study
MMSI
New Projects/Investments
- MMI (Medical Microinstruments, Inc.) has received U.S. Food and Drug Administration (FDA) approval for an Investigational Device Exemption (IDE) for a clinical study.
- The study, named REMIND, will evaluate the Symani® Surgical System for a novel robotic microsurgical intervention for Alzheimer's disease.
- This intervention aims to reestablish lymphatic drainage pathways in the deep cervical lymph nodes to potentially improve the clearance of harmful proteins associated with Alzheimer's.
- The primary endpoint of the study is device-related serious adverse events, with patient enrollment expected to begin soon in the U.S. and Europe.
Nov 5, 2025, 5:16 PM
Quarterly earnings call transcripts for MERIT MEDICAL SYSTEMS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more